433 reports of this reaction
0.9% of all TAPENTADOL HYDROCHLORIDE reports
#11 most reported adverse reaction
FATIGUE is the #11 most commonly reported adverse reaction for TAPENTADOL HYDROCHLORIDE, manufactured by Collegium Pharmaceutical, Inc.. There are 433 FDA adverse event reports linking TAPENTADOL HYDROCHLORIDE to FATIGUE. This represents approximately 0.9% of all 50,606 adverse event reports for this drug.
TAPENTADOL HYDROCHLORIDE has an overall safety score of 92 out of 100. Patients taking TAPENTADOL HYDROCHLORIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for TAPENTADOL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for TAPENTADOL HYDROCHLORIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 433 FDA reports for TAPENTADOL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 0.9% of all adverse event reports for TAPENTADOL HYDROCHLORIDE, making it a notable side effect.
If you experience fatigue while taking TAPENTADOL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.